Enzalutamide Improves Survival in Men With Metastatic Prostate Cancer Enzalutamide Improves Survival in Men With Metastatic Prostate Cancer

Enzalutamide improves 5-year survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer, but increases the risk of fatal adverse events, according to final results from the PREVAIL trial.Reuters Health Information

Source: Medscape Medical News Headlines - July 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news